Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  García Quiroz, Janice ^a,b   García Becerra, Rocío ^a   Barrera, David ^a   Santos, Nancy ^a,b   Avila, Euclides ^a   Ordaz Rosado, David ^a   Rivas Suárez, Mariana ^a   Halhali, Ali ^a   Rodríguez, Pamela ^a   Gamboa Domínguez, Armando ^a   Medina Franco, Heriberto ^a   Camacho, Javier ^b   Larrea, Fernando ^a   Díaz, Lorenza ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CALCITRIOL; CYTOCHROME P450; CYTOCHROME P450 3A4; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; POTASSIUM CHANNEL; PROTEIN CYP24A1; PROTEIN EAG1; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEGRADATION; DRUG POTENTIATION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; WESTERN BLOTTING;

EID: 84866327176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045063     Document Type: Article

References (56)

1. Deeb KK, Trump DL, Johnson CS, (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700.
2. Beer TM, Myrthue A, (2004) Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 3: 373-381.
3. Hansen CM, Binderup L, Hamberg KJ, Carlberg C, (2001) Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 6: D820-848.
4. Garcia-Becerra R, Diaz L, Camacho J, Barrera D, Ordaz-Rosado D, et al. (2010) Calcitriol inhibits Ether-a go-go potassium channel expression and cell proliferation in human breast cancer cells. Exp Cell Res 316: 433-442.
5. Avila E, Garcia-Becerra R, Rodriguez-Rasgado JA, Diaz L, Ordaz-Rosado D, et al. (2010) Calcitriol down-regulates human ether a go-go 1 potassium channel expression in cervical cancer cells. Anticancer Res 30: 2667-2672.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
7. Zinser GM, Welsh J, (2004) Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 25: 2361-2372.
8. Zinser GM, Welsh J, (2004) Effect of Vitamin D3 receptor ablation on murine mammary gland development and tumorigenesis. J Steroid Biochem Mol Biol 89-90: 433-436.
9. Welsh J, (2007) Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 28: 1373-1382.
10. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, et al. (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51: 239-244.
11. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, et al. (2010) Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10: 483.
12. Camacho J, (2006) Ether a go-go potassium channels and cancer. Cancer Lett 233: 1-9.
13. Pardo LA, Stuhmer W, (2008) Eag1 as a cancer target. Expert Opinion on Therapeutic Targets 12: 837-843.
14. Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, et al. (1999) Oncogenic potential of EAG K(+) channels. EMBO J 18: 5540-5547.
15. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, et al. (2006) Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 5: 41.
16. Ouadid-Ahidouch H, Ahidouch A, (2008) K+ channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membr Biol 221: 1-6.
17. Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, et al. (2001) Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether.a-gogo K+ channel. Receptors Channels 7: 345-356.
18. Garcia-Quiroz J, Camacho J, (2011) Astemizole: an old anti-histamine as a new promising anti-cancer drug. Anticancer Agents Med Chem 11: 307-314.
19. Sanderson JT, (2006) The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol Sci 94: 3-21.
20. Fischer MJ, Paulussen JJ, Kok-Van Esterik JA, Van der Heijden VS, De Mol NJ, et al. (1997) Effects of the anti-allergics astemizole and norastemizole on Fc epsilon RI receptor-mediated signal transduction processes. Eur J Pharmacol 322: 97-105.
21. Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, et al. (2007) A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 13: 1216-1223.
22. Beer TM, (2003) Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol Oncol 21: 399-405.
23. Schulz M, Schmoldt A, (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58: 447-474.
24. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, et al. (2003) Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 164: 239-246.
25. Li Z, Bustos V, Miner J, Paulo E, Meng ZH, et al. (1998) Propagation of genetically altered tumor cells derived from fine-needle aspirates of primary breast carcinoma. Cancer Res 58: 5271-5274.
26. Chou TC Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
27. Theodoropoulos C, Demers C, Delvin E, Menard D, Gascon-Barre M, (2003) Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin Endocrinol (Oxf) 58: 489-499.
28. Trump DL, Deeb KK, Johnson CS, (2010) Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 16: 1-9.
29. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD, (2001) Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28: 49-55.
30. Beer TM, Munar M, Henner WD, (2001) A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91: 2431-2439.
31. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, et al. (2002) Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72: 648-659.
32. Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, et al. (2010) CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151: 4301-4312.
33. Peehl DM, Seto E, Feldman D, (2001) Rationale for combination ketoconazole/vitamin D treatment of prostate cancer. Urology 58: 123-126.
34. Yu XP, Hustmyer FG, Garvey WT, Manolagas SC, (1991) Demonstration of a 1,25-dihydroxyvitamin D3-responsive protein in human lymphocytes: immunologic crossreactivity and inverse regulation with the vitamin D receptor. Proc Natl Acad Sci U S A 88: 8347-8351.
35. Diaz L, Martinez-Reza I, Garcia-Becerra R, Gonzalez L, Larrea F, et al. (2011) Calcitriol stimulates prolactin expression in non-activated human peripheral blood mononuclear cells: breaking paradigms. Cytokine 55: 188-194.
36. Costa EM, Feldman D, (1987) Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. Endocrinology 120: 1173-1178.
37. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF, (1992) Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 267: 20082-20086.
38. Pramanik R, Asplin JR, Lindeman C, Favus MJ, Bai S, et al. (2004) Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol 232: 137-143.
39. Yin Y, Ni J, Chen M, Guo Y, Yeh S, (2009) RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clin Cancer Res 15: 190-200.
40. Urruticoechea A, Smith IE, Dowsett M, (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23: 7212-7220.
41. Kill IR, (1996) Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci 109 (Pt 6): 1253-1263.
42. du Manoir S, Guillaud P, Camus E, Seigneurin D, Brugal G, (1991) Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12: 455-463.
43. Scholzen T, Gerdes J, (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322.
44. Ouadid-Ahidouch H, Roudbaraki M, Delcourt P, Ahidouch A, Joury N, et al. (2004) Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression. Am J Physiol Cell Physiol 287: C125-134.
45. Wang QM, Jones JB, Studzinski GP, (1996) Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56: 264-267.
46. Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stuhmer W, et al. (2006) Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference. J Biol Chem 281: 13030-13037.
47. Farias LM, Ocana DB, Diaz L, Larrea F, Avila-Chavez E, et al. (2004) Ether a go-go potassium channels as human cervical cancer markers. Cancer Res 64: 6996-7001.
48. Garcia-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stuhmer W, et al. (2004) Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 124: 301-317.
49. Chen Y, Sanchez A, Rubio ME, Kohl T, Pardo LA,et al. Functional K(v)10.1 channels localize to the inner nuclear membrane. PLoS One 6: e19257.
50. Bortner CD, Hughes FM Jr, Cidlowski JA, (1997) A primary role for K+ and Na+ efflux in the activation of apoptosis. J Biol Chem 272: 32436-32442.
51. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, et al. (2002) Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 299: 730-738.
52. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, et al. (2001) Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 60: 1399-1406.
53. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ, (2002) Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277: 25125-25132.
54. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, et al. (2006) Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 69: 56-65.
55. Slominski AT, Kim TK, Janjetovic Z, Tuckey RC, Bieniek R, et al. (2011) 20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am J Physiol Cell Physiol 300: C526-541.
56. Guyton KZ, Kensler TW, Posner GH, (2003) Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 61: 227-238.